Abstract
It has been well recognized that inflammatory responses are part of pathogenesis for various disorders such as autoimmune diseases. For example, multiple sclerosis (MS) is an inflammatory demyelinating disease of central nervous system that is presumably caused by activated T cells specific for myelin antigens. Rheumatoid arthritis (RA) is also a chronic inflammatory disease characterized by synovial inflammation in which several inflammatory cytokines are involved. On the other hand, Osteopontin (Opn) is a pleiotropic cytokine expressed by activated T cells, dendritic cells (DCs) and macrophages and its expression is up-regulated during inflammation. Secreted form of Opn (s-Opn), which is modified by phosphorylation, glycosylation and proteolytic cleavage with thrombin, has activities as a T helper type 1 (Th1) cytokine and as a chemoattractant for many types of cells through integrin receptors and CD44. Recently, it has been uncovered that intracellular form of Opn (i-Opn) is a critical regulator for Toll like receptor-9 (TLR-9), TLR-7- dependent interferon-α (IFN-α) expression by plasmacytoid DCs and Th17 development. In this review, we have summarized recent progress in understanding of Opns role in variety of inflammatory disorders.
Keywords: Autoimmune disease, Secreted form of Opn, Intracellular form of Opn, Thrombin cleaved form of Opn, Alpha4 integrin, Apha9 integrin, Plasmacytoid DC, Conventional DC
Current Drug Targets
Title: Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Volume: 11 Issue: 4
Author(s): Junko Morimoto, Shigeyuki Kon, Yutaka Matsui and Toshimitsu Uede
Affiliation:
Keywords: Autoimmune disease, Secreted form of Opn, Intracellular form of Opn, Thrombin cleaved form of Opn, Alpha4 integrin, Apha9 integrin, Plasmacytoid DC, Conventional DC
Abstract: It has been well recognized that inflammatory responses are part of pathogenesis for various disorders such as autoimmune diseases. For example, multiple sclerosis (MS) is an inflammatory demyelinating disease of central nervous system that is presumably caused by activated T cells specific for myelin antigens. Rheumatoid arthritis (RA) is also a chronic inflammatory disease characterized by synovial inflammation in which several inflammatory cytokines are involved. On the other hand, Osteopontin (Opn) is a pleiotropic cytokine expressed by activated T cells, dendritic cells (DCs) and macrophages and its expression is up-regulated during inflammation. Secreted form of Opn (s-Opn), which is modified by phosphorylation, glycosylation and proteolytic cleavage with thrombin, has activities as a T helper type 1 (Th1) cytokine and as a chemoattractant for many types of cells through integrin receptors and CD44. Recently, it has been uncovered that intracellular form of Opn (i-Opn) is a critical regulator for Toll like receptor-9 (TLR-9), TLR-7- dependent interferon-α (IFN-α) expression by plasmacytoid DCs and Th17 development. In this review, we have summarized recent progress in understanding of Opns role in variety of inflammatory disorders.
Export Options
About this article
Cite this article as:
Morimoto Junko, Kon Shigeyuki, Matsui Yutaka and Uede Toshimitsu, Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases, Current Drug Targets 2010; 11 (4) . https://dx.doi.org/10.2174/138945010790980321
DOI https://dx.doi.org/10.2174/138945010790980321 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design Progress in Intra-Articular Drug Delivery Systems for Osteoarthritis
Current Drug Targets Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Novel High Throughput Polymer Biocompatibility Screening Designed for SAR (Structure-Activity Relationship): Application for Evaluating Polymer Coatings for Cardiovascular Drug-Eluting Stents
Combinatorial Chemistry & High Throughput Screening Activation and Regulation of Toll-like Receptor 9: CpGs and Beyond
Mini-Reviews in Medicinal Chemistry From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Monoclonal Antibodies in Allergy; Updated Applications and Promising Trials
Recent Patents on Inflammation & Allergy Drug Discovery Lifestyle Modification in Rheumatoid Arthritis: Dietary and Physical Activity Recommendations Based on Evidence
Current Rheumatology Reviews Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets Subject Index To Volume 2
Current Women`s Health Reviews Rheumatoid Arthritis Patients with Sjogrens Syndrome are More Prone to Depression than Patients with Rheumatoid Arthritis or Sjogrens Syndrome Alone
Current Rheumatology Reviews Small Molecule Antagonists of Chemokine Receptors - is Promiscuity a Virtue?
Current Topics in Medicinal Chemistry Role of Cyclooxygenases in Angiogenesis
Current Medicinal Chemistry Current Theories and Clinical Trial Evidence for Limiting Human Abdominal Aortic Aneurysm Growth
Current Drug Targets Synthetic and Natural Immunomodulators Acting as Interferon Inducers
Current Pharmaceutical Design IL-27: Friend or Foe in the Autoimmune Diseases
Current Immunology Reviews (Discontinued) The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
Current Genomics Meet Our Editorial Board Member
Current Medicinal Chemistry